2016 American Society of Clinical Oncology Annual Meeting*

Download All
June 3-7, 2016; Chicago, Illinois
This program provides coverage of the 2016 ASCO annual meeting with PowerPoint summaries and expert analysis of the most clinically relevant study results with downloadable highlights slidesets. Topics include multiple solid tumors and hematologic malignancies.

Gastrointestinal Cancers

Updated data in patients with mismatch repair–deficient metastatic CRC show potential association with treatment response to pembrolizumab.

Released: June 9, 2016

Immunoscore found to be predictive of time to recurrence, disease-free survival, and OS in colon cancer.

Released: June 14, 2016

MEK and PD-L1 inhibitors show potential synergy in MSS and chemorefractory KRAS-mutant mCRC.

Released: June 10, 2016

Tumor location appears to be prognostic of PFS, OS, and predictive of response to biologic agents in KRAS wt mCRC.

Released: June 8, 2016

Subanalysis of phase III RECOURSE trial suggests clinical benefit of TAS-102 in specific patients with metastatic CRC.

Released: June 13, 2016

Survival benefit was consistent across prognostic criteria of grade, disease stage, lymph node involvement, and resection margins, and there was no significant difference in treatment-related serious adverse events between the 2 treatment arms.

Released: June 14, 2016
Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC in collaboration with Postgraduate Institute for Medicine
ACHS Logo

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

This activity is supported by educational grants from
Amgen
Ariad Pharmaceuticals
Bayer HealthCare Pharmaceuticals Inc.
Celgene Corporation
Genentech
Incyte
Merck & Co., Inc.
Taiho Pharmaceuticals

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue